FeesSafety
Pluang+

Retension Pharmaceuticals raises $51.75M in IPO to fund Phase 2b trial of hypertension drug RTN-001, data due H1 2027

Company Fundamentals
18 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Retension Pharmaceuticals raises $51.75M in IPO to fund Phase 2b trial of hypertension drug RTN-001, data due H1 2027

Retension Pharmaceuticals completed an upsized IPO in October 2026, raising $51.75 million to support development of RTN-001 for uncontrolled hypertension affecting 30 million Americans. The company is conducting a Phase 2b clinical trial with topline data expected in the first half of 2027. Retension also strengthened its leadership and scientific advisory board to advance the drug through clinical phases. Financially, the company reported a net loss of $5.9 million for Q3 2026, with a pro forma cash position of $54.3 million including IPO proceeds, positioning it to continue its research and development efforts.

Retension Pharmaceuticals reported a net loss of $5.9 million for Q3 2026 and holds a pro forma cash position of $54.3 million following its upsized IPO. For readers following the health sector, here is Pluang's market snapshot as of Nov 18, 2026 19:21 WIB: out of 150 priced US health stocks, 55 rose and 86 fell today. Notable movers include INO at USD 1.59 with 78% sell order activity, BKD at USD 8.60 with a typical hold time of 9 days, and FLNA at USD 0.47 with 97% sell order activity.

More News

Lowe's beats Q3 earnings estimates and raises full-year sales outlook.

Lowe's beats Q3 earnings estimates and raises full-year sales outlook.

Lowe's reported adjusted earnings per share of $3.10, surpassing estimates of $2.88, and revenue of $22.80 billion, beating the $22.40 billion forecast. Comparable sales rose 1.8%, driven by strong online and professional services sales. The company ...

Company Fundamentals
Bullish
50 minutes ago
Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Daxor Corporation announced that a major Memphis health system has expanded its Blood Volume Analysis (BVA) program to an additional hospital outpatient site using Daxor’s ezBVA Lab service. This expansion allows the outpatient clinic to receive bloo...

Market News
Bullish
54 minutes ago
Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft's stock fell 2.27% to $506.24 following global outages affecting its Copilot, Teams, and Outlook services. The outages, attributed to server issues rather than cyberattacks, raised concerns amid broader software sector weakness. Oppenheimer...

Market News
Bearish
1 hour ago
Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target Corporation reported earnings per share of $2.65, beating estimates of $2.08, and revenue of $27.1 billion, surpassing the $26.5 billion forecast. The company achieved its strongest quarterly sales growth in about five years, with net sales up...

Company Fundamentals
Bullish
1 hour ago
Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App